Navigation Links
Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
Date:6/15/2009

SAN DIEGO, June 15 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.

The LPA1 receptor is part of the Phosphatidic Acid/Lysophosphatidylcholine pathway, which among other things is associated with cell to cell communication. In recent studies, it has been shown to potentially play a role in fibrotic disease, specifically Idiopathic Pulmonary Fibrosis (IPF).

"Our data not only confirms that this pathway may play a role in fibrotic diseases such as IPF, but that we are well on our way to developing an orally available antagonist which could be studied in a human clinical setting," said Peppi Prasit, Ph.D., Chief Scientific Officer. "While a great deal of work remains on this program, we are particularly excited since we believe this could be a novel, first-in-class therapy."

Bob Baltera, Chief Executive Officer, added, "Our LPA1 program is particularly important for Amira. IPF is a specialty focused disease setting and presents the opportunity for Amira to develop a therapeutic through commercialization without the assistance of a strategic partner. Most importantly, IPF is a grievous disease with minimally effective therapeutic options for patients today."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Amira has a partnership w
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
2. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
3. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
6. Amira Pharmaceuticals Appoints First Vice President of Development
7. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
8. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
9. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
10. Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results
11. Isis Pharmaceuticals to Present at Jefferies 3rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Hills, CA (PRWEB) July 25, 2014 Agoura ... a special promotion on Zoom Whitening. Zoom Whitening is one ... is only available through a dental professional. This light-assisted treatment ... into the structure of the tooth to break up stains ... is effective on coffee, tea, wine, soft drink and tobacco ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The rising pharmaceutical ... leading to the growth of the US PBM industry. A ... and value of pharmaceutical sales in the US over the ... be attributed to rise in the prescription volume over the ... Pharmacy Benefit Management (PBM): 2013 Edition” the demand for the ...
(Date:7/25/2014)... July 25, 2014 Ross A. Clevens, ... been invited to join the exclusive Obagi Clinical Advisory ... facial plastic surgeons, plastic surgeons and dermatologists. , ... exclusive Advisory Board of thought leaders held its first ... meeting was to give Obagi the opportunity to meet ...
(Date:7/25/2014)... (HealthDay News) -- Dietary changes can dramatically alter the ... basis, according to a new study. These ... detect and ease flare-ups for people with certain chronic ... Crohn,s disease), the researchers said. Trillions of bacteria ... human health isn,t well understood, the Massachusetts Institute of ...
(Date:7/25/2014)... July 25, 2014 ZeptoMetrix™ Corporation ... reliable and trusted products and services for infectious ... release of NATtrol™ RP Multimarker Controls - ... in vitro diagnostic, CE marked, unassayed external run ... assays the NATtrol™ RP Multimarker Controls - MDZ001 ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2
... joined the protesting medical students on Saturday in the ... Azad Medical College and ended at the Jantar Mantar. ... no sloganeering. The participants also formed a human chain, ... “We do not want to inconvenience anybody. We are ...
... of tsunami-hit Pondicherry beach on Saturday to create a sculptor ... Child' - spreading the message of polio eradication was unveiled ... sculpture with two polio drops to mark the last phase ... ,Thousands of tourists, among them many foreigners, thronged ...
... study conducted, researchers highlight that surgeons can now remove ... facial nerve is not injured//. This study, which investigates ... to describe where and how often the facial nerve ... provide surgeons with adequate knowledge, helping them prevent a ...
... tonsils and adenoids does not result in a compromise ... new study has found. The findings of the present ... pain-free and effective method to remove tonsils and adenoids ... have been discouraged from having monopolar electrosurgery for ear, ...
... the popular belief that only bad dogs bite, it has ... pain can bite, argue pediatricians//. Doesn’t sound alarming? According to ... dogs bite nearly 4.7 million Americans every year. ... 14 years of age and 150,000 of these bites are ...
... ahead and purchased a medical equipment from an internet ... the hospital authorities. Apparently, he had already purchased ?45,000 ... Paget Hospital, Gorleston, Norfolk. A retractor, which was much ... huge order. ,Since a retractor is critical ...
Cached Medicine News:Health News:Study Offers Hope In Prevention Of Facial Paralysis 2Health News:Electrosurgery Ensures Integrity Of Cochlear Implant Following Adenoids Removal 2Health News:Electrosurgery Ensures Integrity Of Cochlear Implant Following Adenoids Removal 3Health News:Watch Out! Even Good Dogs Can Bite Your Kids 2
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... YORK, Dec. 7, 2011 Reportlinker.com announces ... available in its catalogue: ... Japan http://www.reportlinker.com/p0702529/Future-Therapeutic-Drug-Monitoring-Market-US-Europe-Japan.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... TDM market will undergo significant transformation. These ...
... Talyst announces AutoPharm® Mobile, an Apple iOS application ... can be conveniently accessed on an Apple iOS ... across the health system. AutoPharm ... access to medication inventory throughout the health system. ...
Cached Medicine Technology:Future Therapeutic Drug Monitoring Market: US, Europe, Japan 2Future Therapeutic Drug Monitoring Market: US, Europe, Japan 3Future Therapeutic Drug Monitoring Market: US, Europe, Japan 4Future Therapeutic Drug Monitoring Market: US, Europe, Japan 5Future Therapeutic Drug Monitoring Market: US, Europe, Japan 6Future Therapeutic Drug Monitoring Market: US, Europe, Japan 7Future Therapeutic Drug Monitoring Market: US, Europe, Japan 8Future Therapeutic Drug Monitoring Market: US, Europe, Japan 9Talyst Releases AutoPharm Mobile 2
Inquire...
Inquire...
... and simplicity at the point of care: , ... volume of only 70 L of whole blood (all ... after change of sensor cassette , safePICO mixer ensures ... a sample in 7 seconds) * ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
Medicine Products: